目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 43)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
1.8.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 47)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 DRUG DISCOVERY SERVICES MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022
FIGURE 5 ILLUSTRATIVE EXAMPLE OF COMPANY REVENUE ANALYSIS, 2022
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTIONS
FIGURE 7 MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
FIGURE 8 MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY (Page No. - 59)
FIGURE 10 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 11 MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)
FIGURE 12 MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF MARKET, 2022

4 PREMIUM INSIGHTS (Page No. - 63)
4.1 MARKET OVERVIEW
FIGURE 15 INCREASING R&D EXPENDITURE IN PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: MARKET, BY DRUG TYPE AND COUNTRY (2022)
FIGURE 16 SMALL-MOLECULE DRUGS HELD LARGEST SHARE OF NORTH AMERICAN DRUG DISCOVERY MARKET IN 2022
4.3 MARKET SHARE, BY TYPE (2022)
FIGURE 17 CHEMISTRY SERVICES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.4 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 18 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH FROM 2023-2028

5 MARKET OVERVIEW (Page No. - 66)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 4 MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Growing R&D expenditure in pharma-biotech sector
FIGURE 20 RISING GLOBAL PHARMACEUTICAL R&D SPENDING, 2014-2028
5.2.1.2 Increasing drug R&D pipeline and rising reliance on outsourcing
FIGURE 21 ACTIVE PHARMACEUTICAL PIPELINE, 2012-2022
5.2.1.3 Initiatives for research on rare diseases and orphan drugs
FIGURE 22 NUMBER OF DRUGS GIVEN ORPHAN DRUG STATUS (2013-2021)
5.2.1.4 High cost of in-house drug development
FIGURE 23 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010-2020 (USD BILLION)
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulations governing drug discovery and animal usage
5.2.3 OPPORTUNITIES
5.2.3.1 Technological advancements and new drug discovery techniques
5.2.3.2 Rising demand for specialized testing services among end users
5.2.3.3 Patent expiries of key biologics
TABLE 5 US: BIOLOGICS GOING OFF-PATENT DURING 2023-2027
5.2.3.4 High growth prospects in emerging markets
5.2.4 CHALLENGES
5.2.4.1 Shortage of skilled personnel
5.2.5 MARKET TRENDS
5.2.5.1 Adoption of AI in drug discovery
5.2.5.2 Increased outsourcing to emerging Asian economies
5.2.5.3 CRO industry consolidation
TABLE 6 MARKET: PROMINENT ACQUISITIONS, 2023-2021
5.2.5.4 Integrated end-to-end R&D service offerings
5.3 RANGES/SCENARIOS
FIGURE 24 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON MARKET GROWTH
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
FIGURE 25 REVENUE SHIFT AND NEW POCKETS FOR DRUG DISCOVERY SERVICE PROVIDERS
5.5 VALUE CHAIN ANALYSIS
FIGURE 26 VALUE CHAIN ANALYSIS OF MARKET: HIT-TO-LEAD IDENTIFICATION AND LEAD OPTIMIZATION PHASES ADD MAXIMUM VALUE
5.6 ECOSYSTEM ANALYSIS
FIGURE 27 ECOSYSTEM ANALYSIS: MARKET
TABLE 7 SUPPLY CHAIN ECOSYSTEM
5.7 TECHNOLOGY ANALYSIS
5.8 PRICING ANALYSIS
5.8.1 AVERAGE SELLING PRICE TREND ANALYSIS
TABLE 8 DRUG DISCOVERY AND DEVELOPMENT PROCESS & COST OVERVIEW (2018 VS 2022)
5.9 REGULATORY ANALYSIS
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10 PORTER’S FIVE FORCES ANALYSIS
TABLE 13 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.10.1 THREAT OF NEW ENTRANTS
5.10.2 THREAT OF SUBSTITUTES
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 BARGAINING POWER OF SUPPLIERS
5.10.5 INTENSITY OF COMPETITIVE RIVALRY
5.11 KEY CONFERENCES & EVENTS, 2022-2023
TABLE 14 MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DRUG DISCOVERY SERVICES
5.12.2 BUYING CRITERIA FOR DRUG DISCOVERY SERVICES
FIGURE 29 KEY BUYING CRITERIA FOR END USERS

6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS (Page No. - 93)
6.1 INTRODUCTION
TABLE 15 MARKET, BY PROCESS, 2021-2028 (USD MILLION)
6.2 TARGET SELECTION
6.2.1 DEVELOPMENT OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH
TABLE 16 MARKET FOR TARGET SELECTION, BY REGION, 2021-2028 (USD MILLION)
TABLE 17 NORTH AMERICA: MARKET FOR TARGET SELECTION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 18 EUROPE: MARKET FOR TARGET SELECTION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 19 ASIA PACIFIC: MARKET FOR TARGET SELECTION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 20 LATIN AMERICA: MARKET FOR TARGET SELECTION, BY COUNTRY, 2021-2028 (USD MILLION)
6.3 TARGET VALIDATION
6.3.1 EMPHASIS ON TARGET VALIDATION TO AVOID LATE-STAGE FAILURE TO PROMOTE MARKET GROWTH
TABLE 21 MARKET FOR TARGET VALIDATION, BY REGION, 2021-2028 (USD MILLION)
TABLE 22 NORTH AMERICA: MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 23 EUROPE: MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 24 ASIA PACIFIC: MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 25 LATIN AMERICA: MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION)
6.4 HIT-TO-LEAD IDENTIFICATION
6.4.1 HIT-TO-LEAD IDENTIFICATION TO HOLD LARGEST MARKET SHARE
TABLE 26 MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2021-2028 (USD MILLION)
TABLE 27 NORTH AMERICA: MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 28 EUROPE: MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 29 ASIA PACIFIC: MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 30 LATIN AMERICA: MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021-2028 (USD MILLION)
6.5 LEAD OPTIMIZATION
6.5.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST FOCUS ON LEAD OPTIMIZATION
TABLE 31 MARKET FOR LEAD OPTIMIZATION, BY REGION, 2021-2028 (USD MILLION)
TABLE 32 NORTH AMERICA: MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 33 EUROPE: MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 34 ASIA PACIFIC: MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 35 LATIN AMERICA: MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
6.6 CANDIDATE VALIDATION
6.6.1 POSSIBILITY OF DRUG FAILURE DURING DEVELOPMENT TO DRIVE ADOPTION OF CANDIDATE VALIDATION SERVICES
TABLE 36 MARKET FOR CANDIDATE VALIDATION, BY REGION, 2021-2028 (USD MILLION)
TABLE 37 NORTH AMERICA: MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 38 EUROPE: MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 39 ASIA PACIFIC: MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 40 LATIN AMERICA: MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION)

7 DRUG DISCOVERY SERVICES MARKET, BY TYPE (Page No. - 109)
7.1 INTRODUCTION
TABLE 41 MARKET, BY TYPE, 2021-2028 (USD MILLION)
7.2 CHEMISTRY SERVICES
7.2.1 CHEMISTRY SERVICES TO DOMINATE SERVICE TYPE MARKET
TABLE 42 CHEMISTRY SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 43 NORTH AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 44 EUROPE: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 45 ASIA PACIFIC: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 46 LATIN AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
7.3 BIOLOGY SERVICES
7.3.1 RESTRICTIONS ON ANIMAL USAGE TO SLOW MARKET GROWTH
TABLE 47 BIOLOGY SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 48 NORTH AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 49 EUROPE: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 50 ASIA PACIFIC: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 51 LATIN AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE (Page No. - 116)
8.1 INTRODUCTION
TABLE 52 MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
8.2 SMALL-MOLECULE DRUGS
8.2.1 SMALL-MOLECULE DRUGS TO HOLD LARGEST MARKET SHARE
TABLE 53 MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2021-2028 (USD MILLION)
TABLE 54 NORTH AMERICA: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 55 EUROPE: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 56 ASIA PACIFIC: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 57 LATIN AMERICA: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)
8.3 BIOLOGICS
8.3.1 MARKET GROWTH OF BIOLOGICS & CHALLENGES ASSOCIATED WITH DISCOVERY TO DRIVE ADOPTION OF OUTSOURCING SERVICES
TABLE 58 MARKET FOR BIOLOGICS, BY REGION, 2021-2028 (USD MILLION)
TABLE 59 NORTH AMERICA: MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 60 EUROPE: MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 61 ASIA PACIFIC: MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 62 LATIN AMERICA: MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION)

9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA (Page No. - 124)
9.1 INTRODUCTION
TABLE 63 MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
9.2 ONCOLOGY
9.2.1 HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH
FIGURE 30 NUMBER OF ONCOLOGY CLINICAL TRIALS, 2012-2022 (THOUSAND)
TABLE 64 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2022)
TABLE 65 MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)
TABLE 66 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 67 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 68 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 69 LATIN AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
9.3 INFECTIOUS DISEASES
9.3.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY
TABLE 70 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
TABLE 71 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 72 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 73 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 74 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
9.4 CARDIOVASCULAR DISEASES
9.4.1 HIGH MORTALITY RATES PROMPTING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS
TABLE 75 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (AS OF DECEMBER 2022)
TABLE 76 MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021-2028 (USD MILLION)
TABLE 77 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 78 EUROPE: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 79 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 80 LATIN AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
9.5 NEUROLOGICAL DISEASES
9.5.1 INCREASING INVESTMENTS IN R&D FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET
TABLE 81 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2022)
TABLE 82 MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2021-2028 (USD MILLION)
TABLE 83 NORTH AMERICA: MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 84 EUROPE: MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 85 ASIA PACIFIC: MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 86 LATIN AMERICA: MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
9.6 IMMUNOLOGICAL DISORDERS
9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH
TABLE 87 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022)
TABLE 88 MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
TABLE 89 NORTH AMERICA: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 90 EUROPE: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 91 ASIA PACIFIC: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 92 LATIN AMERICA: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
9.7 ENDOCRINE & METABOLIC DISORDERS
9.7.1 INCREASING DIABETIC POPULATION TO BOOST MARKET
FIGURE 31 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000-2045 (MILLION)
TABLE 93 MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2021-2028 (USD MILLION)
TABLE 94 NORTH AMERICA: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 95 EUROPE: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 96 ASIA PACIFIC: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 97 LATIN AMERICA: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
9.8 RESPIRATORY DISORDERS
9.8.1 RISING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH
TABLE 98 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISORDERS (2022)
TABLE 99 MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2021-2028 (USD MILLION)
TABLE 100 NORTH AMERICA: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 101 EUROPE: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 102 ASIA PACIFIC: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 103 LATIN AMERICA: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
9.9 DIGESTIVE SYSTEM DISEASES
9.9.1 RISING DISEASE INCIDENCE DUE TO LIFESTYLE AND DIETARY CHANGES TO PROPEL MARKET
TABLE 104 MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2021-2028 (USD MILLION )
TABLE 105 NORTH AMERICA: MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 106 EUROPE: MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 107 ASIA PACIFIC: MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 108 LATIN AMERICA: MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
9.10 GENITOURINARY DISEASES & WOMEN’S HEALTH
9.10.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO BOOST MARKET
TABLE 109 MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY REGION, 2021-2028 (USD MILLION)
TABLE 110 NORTH AMERICA: MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 111 EUROPE: MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 112 ASIA PACIFIC: MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 113 LATIN AMERICA: MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021-2028 (USD MILLION)
9.11 OTHER THERAPEUTIC AREAS
TABLE 114 MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021-2028 (USD MILLION)
TABLE 115 NORTH AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 116 EUROPE: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 117 ASIA PACIFIC: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 118 LATIN AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)

10 DRUG DISCOVERY SERVICES MARKET, BY END USER (Page No. - 155)
10.1 INTRODUCTION
TABLE 119 MARKET, BY END USER, 2021-2028 (USD MILLION)
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
FIGURE 32 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2011-2021
TABLE 120 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
TABLE 121 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 122 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 123 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 124 LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
10.2.1 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE
TABLE 125 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
10.2.2 TIER 1 COMPANIES
10.2.2.1 High investing capacity to drive growth
TABLE 126 TOP PHARMA COMPANIES, BY REVENUE (2022)
TABLE 127 MARKET FOR TIER 1 COMPANIES, BY REGION, 2021-2028 (USD MILLION)
TABLE 128 NORTH AMERICA: MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 129 EUROPE: MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 130 ASIA PACIFIC: MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 131 LATIN AMERICA: MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
10.2.3 TIER 2 COMPANIES
10.2.3.1 Limited investment capacity to slow market growth
TABLE 132 MARKET FOR TIER 2 COMPANIES, BY REGION, 2021-2028 (USD MILLION)
TABLE 133 NORTH AMERICA: MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 134 EUROPE: MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 135 ASIA PACIFIC: MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 136 LATIN AMERICA: MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
10.2.4 TIER 3 COMPANIES
10.2.4.1 Insufficient technical advantages to restrain growth
TABLE 137 MARKET FOR TIER 3 COMPANIES, BY REGION, 2021-2028 (USD MILLION)
TABLE 138 NORTH AMERICA: MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 139 EUROPE: MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 140 ASIA PACIFIC: MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 141 LATIN AMERICA: MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
10.3 ACADEMIC INSTITUTES
10.3.1 COLLABORATION WITH MARKET PLAYERS TO PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT
TABLE 142 MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
TABLE 143 NORTH AMERICA: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 144 EUROPE: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 145 ASIA PACIFIC: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 146 LATIN AMERICA: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
10.4 OTHER END USERS
TABLE 147 MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)
TABLE 148 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 149 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 150 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 151 LATIN AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)

11 DRUG DISCOVERY SERVICES MARKET, BY REGION (Page No. - 172)
11.1 INTRODUCTION
TABLE 152 MARKET, BY REGION, 2021-2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 33 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2022)
TABLE 153 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 154 NORTH AMERICA: MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 155 NORTH AMERICA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 156 NORTH AMERICA: SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 157 NORTH AMERICA: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 158 NORTH AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 159 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.2.1 US
11.2.1.1 US to dominate North American market
FIGURE 34 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022)
TABLE 160 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 161 US: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 162 US: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 163 US: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 164 US: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 165 US: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Growing preference to conduct clinical trials in Canada to support market growth
TABLE 166 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 167 CANADA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 168 CANADA: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 169 CANADA: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 170 CANADA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 171 CANADA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.2.3 NORTH AMERICA: RECESSION IMPACT
11.3 EUROPE
TABLE 172 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 173 EUROPE: MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 174 EUROPE: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 175 EUROPE: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 176 EUROPE: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 177 EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 178 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Germany to hold largest share of European market
TABLE 179 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 180 GERMANY: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 181 GERMANY: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 182 GERMANY: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 183 GERMANY: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 184 GERMANY: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.3.2 UK
11.3.2.1 Government-private sector collaborations to boost market
TABLE 185 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 186 UK: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 187 UK: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 188 UK: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 189 UK: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 190 UK: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Growing number of oncology research projects to propel market
TABLE 191 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 192 FRANCE: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 193 FRANCE: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 194 FRANCE: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 195 FRANCE: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 196 FRANCE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.3.4 ITALY
11.3.4.1 High number of clinical trials and low drug approval time to augment market
TABLE 197 NUMBER OF CLINICAL TRIALS IN ITALY, BY COMPANY (JANUARY 2022)
TABLE 198 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 199 ITALY: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 200 ITALY: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 201 ITALY: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 202 ITALY: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 203 ITALY: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Short study start-up times and rising R&D expenditure to augment market
TABLE 204 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 205 SPAIN: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 206 SPAIN: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 207 SPAIN: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 208 SPAIN: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 209 SPAIN: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 210 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 211 REST OF EUROPE: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 212 REST OF EUROPE: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 213 REST OF EUROPE: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 214 REST OF EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 215 REST OF EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.3.7 EUROPE: RECESSION IMPACT
11.4 ASIA PACIFIC
FIGURE 35 APAC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2022)
TABLE 216 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 217 ASIA PACIFIC: MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 218 ASIA PACIFIC: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 219 ASIA PACIFIC: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 220 ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 221 ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 222 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Robust pharma industry and presence of key CROs to account for China’s large market share
TABLE 223 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 224 CHINA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 225 CHINA: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 226 CHINA: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 227 CHINA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 228 CHINA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Government initiatives for drug innovation to support market growth
TABLE 229 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2020 VS. 2022
TABLE 230 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 231 JAPAN: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 232 JAPAN: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 233 JAPAN: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 234 JAPAN: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 235 JAPAN: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Low-cost services, availability of skilled workforce, and strong government support to propel market
TABLE 236 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 237 INDIA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 238 INDIA: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 239 INDIA: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 240 INDIA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 241 INDIA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.4.4 AUSTRALIA
11.4.4.1 Large number of clinical trials to make Australia a favorable location for drug discovery
TABLE 242 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 243 AUSTRALIA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 244 AUSTRALIA: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 245 AUSTRALIA: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 246 AUSTRALIA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 247 AUSTRALIA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 Government initiatives and growing R&D activities for drug development to drive growth
TABLE 248 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 249 SOUTH KOREA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 250 SOUTH KOREA: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 251 SOUTH KOREA: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 252 SOUTH KOREA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 253 SOUTH KOREA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.4.6 REST OF ASIA PACIFIC
TABLE 254 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 255 REST OF ASIA PACIFIC: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 256 REST OF ASIA PACIFIC: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 257 REST OF ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 258 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 259 REST OF ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.4.7 ASIA PACIFIC: RECESSION IMPACT
11.5 LATIN AMERICA
TABLE 260 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 261 LATIN AMERICA: MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 262 LATIN AMERICA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 263 LATIN AMERICA: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 264 LATIN AMERICA: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 265 LATIN AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 266 LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Brazil to dominate Latin American market
TABLE 267 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 268 BRAZIL: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 269 BRAZIL: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 270 BRAZIL: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 271 BRAZIL: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 272 BRAZIL: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.5.2 REST OF LATIN AMERICA
TABLE 273 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 274 REST OF LATIN AMERICA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 275 REST OF LATIN AMERICA: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 276 REST OF LATIN AMERICA: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 277 REST OF LATIN AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 278 REST OF LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.5.3 LATIN AMERICA: RECESSION IMPACT
11.6 MIDDLE EAST & AFRICA
11.6.1 GROWING PHARMACEUTICAL INDUSTRY TO BOOST MARKET
TABLE 279 MIDDLE EAST & AFRICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
TABLE 280 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 281 MIDDLE EAST & AFRICA: MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
TABLE 282 MIDDLE EAST & AFRICA: MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
TABLE 283 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 284 MIDDLE EAST & AFRICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION)
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE (Page No. - 246)
12.1 OVERVIEW
12.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS
FIGURE 36 KEY STRATEGIES ADOPTED BY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2020-2023
12.3 MARKET SHARE ANALYSIS
FIGURE 37 MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
TABLE 285 MARKET: DEGREE OF COMPETITION
12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS, 2020-2022
12.5 COMPANY EVALUATION QUADRANT
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 39 MARKET: COMPANY EVALUATION QUADRANT, 2022
12.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 40 MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
12.7 COMPANY FOOTPRINT ANALYSIS
12.7.1 COMPANY SERVICE FOOTPRINT
TABLE 286 SERVICE PORTFOLIO ANALYSIS: MARKET (2022)
12.7.2 COMPANY GEOGRAPHIC FOOTPRINT
TABLE 287 GEOGRAPHIC REVENUE MIX: MARKET (2022)
12.8 COMPETITIVE SCENARIO
TABLE 288 MARKET: SERVICE LAUNCHES, JANUARY 2020-MARCH 2023
TABLE 289 MARKET: DEALS, JANUARY 2020-MARCH 2023
TABLE 290 DRUG DISCOVERY SERVICES MARKET: EXPANSION: JANUARY 2020-MARCH 2023

13 COMPANY PROFILES (Page No. - 259)
13.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS
TABLE 291 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
FIGURE 41 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)
13.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
TABLE 292 CHARLES RIVER LABORATORIES INTERNATIONAL: BUSINESS OVERVIEW
FIGURE 42 CHARLES RIVER LABORATORIES INTERNATIONAL: COMPANY SNAPSHOT (2022)
13.1.3 WUXI APPTEC
TABLE 293 WUXI APPTEC: BUSINESS OVERVIEW
FIGURE 43 WUXI APPTEC: COMPANY SNAPSHOT (2021)
13.1.4 THERMO FISHER SCIENTIFIC
TABLE 294 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 44 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT (2022)
13.1.5 PHARMARON BEIJING CO., LTD.
TABLE 295 PHARMARON BEIJING CO., LTD.: BUSINESS OVERVIEW
FIGURE 45 PHARMARON BEIJING CO., LTD.: COMPANY SNAPSHOT (2021)
13.1.6 EVOTEC SE
TABLE 296 EVOTEC SE: BUSINESS OVERVIEW
FIGURE 46 EVOTEC SE: COMPANY SNAPSHOT (2021)
13.1.7 EUROFINS SCIENTIFIC SE
TABLE 297 EUROFINS SCIENTIFIC SE: BUSINESS OVERVIEW
FIGURE 47 EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT (2022)
13.1.8 PIRAMAL ENTERPRISES LIMITED
TABLE 298 PIRAMAL ENTERPRISES LIMITED: BUSINESS OVERVIEW
FIGURE 48 PIRAMAL ENTERPRISES LIMITED: COMPANY SNAPSHOT (2021)
13.1.9 SYNGENE INTERNATIONAL LIMITED
TABLE 299 SYNGENE INTERNATIONAL LIMITED: BUSINESS OVERVIEW
FIGURE 49 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2021)
13.1.10 CURIA GLOBAL INC.
TABLE 300 CURIA GLOBAL INC.: BUSINESS OVERVIEW
13.1.11 GENSCRIPT BIOTECH CORPORATION
TABLE 301 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW
FIGURE 50 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2021)
13.1.12 JUBILANT PHARMOVA LIMITED
TABLE 302 JUBILANT PHARMOVA LIMITED: BUSINESS OVERVIEW
FIGURE 51 JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2021)
13.1.13 FRONTAGE HOLDINGS CORPORATION
TABLE 303 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 52 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021)
13.1.14 SHANGHAI MEDICILON INC.
TABLE 304 SHANGHAI MEDICILON INC.: BUSINESS OVERVIEW
13.1.15 AURIGENE DISCOVERY TECHNOLOGIES (DR. REDDY’S LABORATORIES)
TABLE 305 DR. REDDY’S LABORATORIES LTD.: BUSINESS OVERVIEW
FIGURE 53 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2021)
13.1.16 SYGNATURE DISCOVERY LTD.
TABLE 306 SYGNATURE DISCOVERY LTD: BUSINESS OVERVIEW
13.1.17 ONCODESIGN SERVICES
TABLE 307 ONCODESIGN SERVICES: BUSINESS OVERVIEW
FIGURE 54 ONCODESIGN SERVICES: COMPANY SNAPSHOT (2021)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER COMPANIES
13.2.1 SELVITA S.A.
13.2.2 VIVA BIOTECH HOLDINGS
13.2.3 TCG LIFESCIENCES PVT LTD.
13.2.4 SHANGHAI CHEMPARTNER CO., LTD.
13.2.5 DOMAINEX LTD.
13.2.6 NUVISAN PHARMA HOLDING GMBH
13.2.7 DALTON PHARMA SERVICES
13.2.8 ARAGEN LIFE SCIENCES PVT. LTD.
13.2.9 PROMEGA CORPORATION

14 APPENDIX (Page No. - 340)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS